Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04565795 · ClinicalTrials.gov registry record · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
A NA study of Ureteral Diseases, sponsored by Adva-Tec.
- Recruiting
- Registry status
- NA
- Development phase
- 87
- Enrollment target
- 4
- Study locations
NCT04565795: Recruiting NA study of Ureteral Diseases, sponsored by Adva-Tec.
NCT04565795 is a NA study of Ureteral Diseases that is actively recruiting participants, run by Adva-Tec. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04565795, a NA study of Ureteral Diseases, is actively recruiting participants, sponsored by Adva-Tec.
- RECRUITING
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
- 4
- Study locations
Study Summary
A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent.
Primary Outcome
Study Success defined as adequate short-term urine drainage, defined as the presence of the stent in the ureter and the lack of surgical or invasive intervention to treat symptoms in the stented ureter during the first 48 hours following placement.
Conditions Studied
Interventions
- DEVICE Uriprene® Degradable Temporary Ureteral Stent
Study Locations (4)
Arizona
- Mayo Clinic Arizona - Phoenix
California
- University of California Los Angeles - Los Angeles
Florida
- University of Florida - Gainesville
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2026-09 |
| Phase | NA |
What NCT04565795 shows while recruiting
NCT04565795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Ureteral Diseases appearing as the primary indexed condition, and to 1 intervention - of which Uriprene® Degradable Temporary Ureteral Stent is the first listed.
NCT04565795 reports a single indexed study location in Arizona, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04565795 about?
NCT04565795 is a clinical study titled "Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy". A prospective, multi-center, non-randomized trial to demonstrate safety and device performance of the ADVA-Tec Uriprene® Degradable Temporary Ureteral Stent.
What is the current status of trial NCT04565795?
This trial is currently recruiting. It is a NA study. The enrollment target is 87 participants. The study started on 2022-07-01. Estimated completion is 2026-09.
What conditions does trial NCT04565795 study?
This clinical trial studies the following conditions: Ureteral Diseases.
What interventions are being tested in trial NCT04565795?
The interventions under investigation include: Uriprene® Degradable Temporary Ureteral Stent (DEVICE).
Who is sponsoring clinical trial NCT04565795?
This trial is sponsored by Adva-Tec, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04565795 being conducted?
This trial has 4 study locations across Arizona, California, Florida, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ureteral Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04565795's enrollment target sits among peer trials
87 975th of 2000 higher than 1,025 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- NCT05635643 · 87 participants · Phase 1
Study of CHS-114 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI